Monopar Therapeutics (MNPR) in collaboration with Excel Diagnostics and Nuclear Oncology Center, EDNOC, a premier diagnostic medical imaging and therapeutic nuclear medicine center, announced that the physician-sponsored Expanded Access Program, EAP, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu has received authorization to proceed from the U.S. Food and Drug Administration. “We are pleased to provide patients in the United States with access to MNPR-101-Zr and MNPR-101-Lu, which were developed to target aggressive cancers, such as triple-negative breast, pancreatic, and colorectal cancer,” said Andrew Cittadine, Chief Operating Officer of Monopar. “This EAP represents continued progress in our radiopharmaceutical pipeline following last year’s initiation of Phase 1 clinical trials in Australia with MNPR-101-Zr and MNPR-101-Lu. We are grateful for the opportunity to work with Dr. Delpassand to make these therapies available to patients on a compassionate use basis,” added Cittadine.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Salesforce initiated, Dollar Tree upgraded: Wall Street’s top analyst calls
- Monopar Therapeutics initiated with a Buy at Lucid Capital
- Monopar Therapeutics announces inclusion in Russell 3000, Russell 2000
- Monopar Therapeutics reports Q1 EPS (38c), consensus (57c)
- Monopar Therapeutics Highlights ALXN1840 Data at EASL 2025